Bolt Biotherapeutics, Inc. ( (BOLT) ) has released its Q2 earnings. Here is a breakdown of the information Bolt Biotherapeutics, Inc. presented to its investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer treatment, leveraging its expertise in myeloid biology to enhance the immune system’s response against tumors. In its latest earnings report for the quarter ending June 30, 2025, the company highlighted key financial metrics and strategic developments. The company reported a net loss of $8.6 million for the quarter, a significant improvement compared to the $21.2 million loss in the same period last year. This reduction in losses was primarily due to decreased operating expenses, which fell from $23.9 million to $11.0 million, reflecting a strategic restructuring and cost management efforts. Despite the ongoing challenges, Bolt Biotherapeutics reported collaboration revenue of $1.8 million, up from $1.3 million in the previous year, indicating progress in its partnerships. Looking ahead, the company remains focused on advancing its clinical programs and securing additional capital to sustain operations through mid-2026, as it navigates uncertainties in the macroeconomic environment and the biopharmaceutical industry.